Abivax S.A. (NASDAQ: AAVXF)

Abivax S.A., a clinical-stage biotechnology company (Euronext: ABVX, Nasdaq: ABVX), operates in the pharmaceutical industry, specifically focusing on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

Abivax S.A., headquartered in France, was incorporated in 2013 and has been listed on Euronext Paris since 2015. The company has a wholly-owned subsidiary, Abivax LLC, based in Delaware. In 2023, Abivax S.A. completed an initial public offering (IPO) on the Nasdaq Global Market, raising approximately $235.8 million in gross proceeds.

The company's primary business activities revolve around the development of therapeutics for chronic inflammatory diseases, with a particular focus on ulcerative colitis (UC) and Crohn's disease (CD). Abivax S.A. differentiates itself from competitors through its unique mechanism of action, specifically enhancing the expression of micro-RNA, miR-124, which plays a critical role in regulating the inflammatory response.

Abivax S.A. generates revenue through the development and potential future commercialization of its lead drug candidate, obefazimod. This novel oral therapy has demonstrated promising results in clinical trials for UC and CD, showing a significant reduction in symptoms and a high rate of clinical remission. The most commonly reported adverse event has been mild to moderate headaches.

Within the industry, key competitors include companies developing therapies for chronic inflammatory diseases. Abivax S.A.'s competitive advantage lies in its unique mechanism of action and the promising results demonstrated by obefazimod in clinical trials.

Unfortunately, the text provided does not include specific names of customers. However, the primary customer base for Abivax S.A. would consist of patients with chronic inflammatory diseases, particularly UC and CD.

Abivax S.A.'s product portfolio includes obefazimod, a novel oral therapy targeting the immune response in patients with chronic inflammatory diseases. Additionally, the company is generating follow-on compounds based on the miR-124 platform and evaluating potential inflammatory indications to pursue.